Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 2
1998 1
2005 1
2006 2
2007 1
2011 1
2012 1
2013 1
2014 1
2015 1
2018 1
2021 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
A Community Hospital-Based Study: A Prespecified Neutrophil Count with Adjuvant mFOLFOX6 Associated with Increased Delays, Increased G-CSF Use, and Reduced Dose Intensity.
Chiarotto JA, Dranitsaris G. Chiarotto JA, et al. Cancer Manag Res. 2021 May 19;13:4087-4094. doi: 10.2147/CMAR.S307713. eCollection 2021. Cancer Manag Res. 2021. PMID: 34040446 Free PMC article.
There were delays for 8.8% of visits for cycles not supported by G-CSF and, surprisingly, 15.9% of visits for cycles supported by G-CSF. Neutropenia caused 61.6% of delays for chemotherapy cycles not supported by G-CSF and 44.1% for cycles supported by G …
There were delays for 8.8% of visits for cycles not supported by G-CSF and, surprisingly, 15.9% of visits for cycles supported by …
Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma.
Dranitsaris G, Sutcliffe SB. Dranitsaris G, et al. Leuk Lymphoma. 1995 Mar;17(1-2):139-45. doi: 10.3109/10428199509051714. Leuk Lymphoma. 1995. PMID: 7539658 Clinical Trial.
The administration of G-CSF resulted in a savings of approximately $1580/patient relative to control. ...The initial G-CSF expenditure would be offset by reduced hospitalization....
The administration of G-CSF resulted in a savings of approximately $1580/patient relative to control. ...The initial G-CSF exp …
Does prolonging the time to testicular cancer surgery impact long-term cancer control: a systematic review of the literature.
Bell D, Morash C, Dranitsaris G, Izawa J, Short T, Klotz LH, Fleshner N; Canadian surgical wait times (SWAT) initiative. Bell D, et al. Can J Urol. 2006 Jun;13 Suppl 3:30-6. Can J Urol. 2006. PMID: 16818010 Review.
RESULTS: Five studies evaluating different components of wait times (e.g. delay in diagnosis, delay in orchiectomy) in testicular cancer patients were identified, four of which measured the impact of prolonged delays on relapse free and overall survival. ...
RESULTS: Five studies evaluating different components of wait times (e.g. delay in diagnosis, delay in orchiectomy) in testicular can …
Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use.
Pasic I, Alanazi W, Dranitsaris G, Lieberman L, Viswabandya A, Kim DDH, Lipton JH, Michelis FV. Pasic I, et al. Hematol Oncol Stem Cell Ther. 2021 Dec;14(4):302-310. doi: 10.1016/j.hemonc.2021.01.001. Epub 2021 Feb 23. Hematol Oncol Stem Cell Ther. 2021. PMID: 33684377 Free article.
METHODS: A total of 20 eligible patients were treated with SCIG at 0.1 g/kg/week for up to 6 months. Patients were matched to 20 concurrent intravenous immunoglobulin (IVIG) controls. ...
METHODS: A total of 20 eligible patients were treated with SCIG at 0.1 g/kg/week for up to 6 months. Patients were matched to 20 conc …
A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting.
Dranitsaris G, Beegle N, Kalberer T, Blau S, Cox D, Faria C. Dranitsaris G, et al. J Oncol Pharm Pract. 2015 Jun;21(3):170-7. doi: 10.1177/1078155214525369. Epub 2014 Mar 11. J Oncol Pharm Pract. 2015. PMID: 24620009
BACKGROUND: Capecitabine (C), gemcitabine (G), and vinorelbine (V) are commonly used as single agents in patients with metastatic breast cancer. ...The proportion reporting at least one adverse event (any grade) with C, G, V, and E was 45%, 65%, 75%, and 63%. The mo …
BACKGROUND: Capecitabine (C), gemcitabine (G), and vinorelbine (V) are commonly used as single agents in patients with metastatic bre …
Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience.
Zhu X, Bouganim N, Vandermeer L, Dent SF, Dranitsaris G, Clemons MJ. Zhu X, et al. Curr Oncol. 2012 Aug;19(4):e239-43. doi: 10.3747/co.19.948. Curr Oncol. 2012. PMID: 22876152 Free PMC article.
Of the 36 patients, 7 (19%) received g-csf after neutropenia, including 2 who had febrile neutropenia. ...Delivery of g-csf by home-care nurses was well received by patients....
Of the 36 patients, 7 (19%) received g-csf after neutropenia, including 2 who had febrile neutropenia. ...Delivery of g-csf by …
Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective.
Couban S, Dranitsaris G, Andreou P, Price S, Tinker L, Foley R, Walker IR, Jamal S, Jamal N, Spaner D, Lipton J, Meharchand J, Messner HA. Couban S, et al. Bone Marrow Transplant. 1998 Dec;22(12):1199-205. doi: 10.1038/sj.bmt.1701504. Bone Marrow Transplant. 1998. PMID: 9894724
We compared harvest characteristics, donor and recipient outcomes and costs of two PBPC transplant strategies with historical controls who received BMT. Twenty donors mobilized with four daily s.c. G-CSF doses (5 microg/kg/day) (group 1) and 20 mobilized with 10 microg/kg/ …
We compared harvest characteristics, donor and recipient outcomes and costs of two PBPC transplant strategies with historical controls who r …
15 results